4D Molecular Therapeutics (FDMT) Stock Forecast, Price Target & Predictions
FDMT Stock Forecast
4D Molecular Therapeutics stock forecast is as follows: an average price target of $41.00 (represents a 413.14% upside from FDMT’s last price of $7.99) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
FDMT Price Target
FDMT Analyst Ratings
Buy
4D Molecular Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 19, 2024 | Kostas Biliouris | BMO Capital | $40.00 | $13.28 | 201.20% | 400.63% |
Sep 19, 2024 | Geulah Livshits | Loop Capital Markets | $39.00 | $13.31 | 192.99% | 388.11% |
Sep 19, 2024 | Matthew Caufield | H.C. Wainwright | $36.00 | $13.31 | 170.44% | 350.56% |
Apr 15, 2024 | Lisa Walter | RBC Capital | $40.00 | $26.35 | 51.80% | 400.63% |
Apr 15, 2024 | Gena Wang | Barclays | $45.00 | $26.35 | 70.78% | 463.20% |
Apr 01, 2024 | Nalin Tejavibulya | Jefferies | $58.00 | $31.86 | 82.05% | 625.91% |
Mar 28, 2024 | Kostas Biliouris | BMO Capital | $63.00 | $31.59 | 99.43% | 688.49% |
Feb 06, 2024 | Kostas Biliouris | BMO Capital | $70.00 | $30.70 | 127.98% | 776.10% |
Jul 05, 2023 | Geulah Livshits | Chardan Capital | $30.00 | $18.43 | 62.78% | 275.47% |
Nov 18, 2022 | - | H.C. Wainwright | $36.00 | $22.40 | 60.71% | 350.56% |
10
4D Molecular Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 3 | 8 |
Avg Price Target | - | $38.33 | $48.88 |
Last Closing Price | $7.99 | $7.99 | $7.99 |
Upside/Downside | -100.00% | 379.72% | 511.76% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 23, 2024 | Cantor Fitzgerald | - | Neutral | Downgrade |
Sep 19, 2024 | BMO Capital | Outperform | Outperform | Hold |
Sep 19, 2024 | Chardan Capital | Buy | Buy | Hold |
Sep 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 09, 2024 | Chardan Capital | Underperform | Underperform | Hold |
Sep 09, 2024 | RBC Capital | Buy | Buy | Hold |
Jul 22, 2024 | RBC Capital | Outperform | Outperform | Hold |
Jul 18, 2024 | RBC Capital | Buy | Buy | Hold |
Jun 07, 2024 | Jefferies | Underperform | Underperform | Hold |
Jun 07, 2024 | RBC Capital | Buy | Buy | Hold |
10
4D Molecular Therapeutics Financial Forecast
4D Molecular Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $-20.74M | $20.20M | $239.00K | $298.00K | $1.25M | $500.00K | $162.00K | $1.22M | $92.00K | $1.37M | $14.58M | $2.00M |
Avg Forecast | $250.00K | $166.67K | $168.33K | $176.00K | $1.47M | $1.62M | $1.27M | $1.45M | $8.07M | $848.33K | $1.28M | $873.40K | $376.25K | $856.00K | $758.33K | $900.00K | $900.00K | $587.50K | $562.50K | $2.60M |
High Forecast | $587.15K | $391.44K | $395.35K | $413.36K | $2.58M | $1.63M | $1.27M | $1.45M | $21.25M | $1.99M | $3.02M | $2.05M | $883.67K | $856.00K | $758.33K | $900.00K | $900.00K | $587.50K | $562.50K | $3.12M |
Low Forecast | $28.44K | $18.96K | $19.15K | $20.02K | $18.43K | $1.60M | $1.27M | $1.45M | $345.48K | $96.51K | $146.18K | $99.36K | $42.80K | $856.00K | $758.33K | $900.00K | $900.00K | $587.50K | $562.50K | $2.08M |
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 5 | 8 |
Surprise % | - | - | - | - | - | - | - | - | -2.57% | 23.82% | 0.19% | 0.34% | 3.31% | 0.58% | 0.21% | 1.35% | 0.10% | 2.33% | 25.92% | 0.77% |
Forecast
4D Molecular Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 5 | 8 |
EBITDA | - | - | - | - | - | - | - | - | $-29.80M | $-12.58M | $-32.14M | $-30.11M | $-27.33M | $-25.62M | $-27.59M | $-25.61M | $-23.20M | $-21.86M | $-7.22M | $-16.02M |
Avg Forecast | $-250.00K | $-166.67K | $-168.33K | $-176.00K | $-1.47M | $-1.62M | $-1.27M | $-1.45M | $-8.07M | $-848.33K | $-1.28M | $-873.40K | $-376.25K | $-856.00K | $-758.33K | $-25.24M | $-900.00K | $-587.50K | $-562.50K | $-20.85M |
High Forecast | $-28.44K | $-18.96K | $-19.15K | $-20.02K | $-18.43K | $-1.60M | $-1.27M | $-1.45M | $-345.48K | $-96.51K | $-146.18K | $-99.36K | $-42.80K | $-856.00K | $-758.33K | $-20.19M | $-900.00K | $-587.50K | $-562.50K | $-16.68M |
Low Forecast | $-587.15K | $-391.44K | $-395.35K | $-413.36K | $-2.58M | $-1.63M | $-1.27M | $-1.45M | $-21.25M | $-1.99M | $-3.02M | $-2.05M | $-883.67K | $-856.00K | $-758.33K | $-30.29M | $-900.00K | $-587.50K | $-562.50K | $-25.02M |
Surprise % | - | - | - | - | - | - | - | - | 3.69% | 14.83% | 25.01% | 34.47% | 72.64% | 29.93% | 36.39% | 1.01% | 25.77% | 37.20% | 12.83% | 0.77% |
Forecast
4D Molecular Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 5 | 8 |
Net Income | - | - | - | - | - | - | - | - | $-33.71M | $-10.26M | $-29.62M | $-27.26M | $-27.27M | $-24.09M | $-27.41M | $-26.18M | $-25.08M | $-22.24M | $-7.59M | $-16.41M |
Avg Forecast | $-57.78M | $-55.37M | $-52.22M | $-48.33M | $-47.22M | $-37.55M | $-38.01M | $-41.16M | $-34.07M | $-43.54M | $-49.63M | $-43.65M | $-46.89M | $-46.77M | $-44.92M | $-26.01M | $-46.99M | $-37.59M | $-45.88M | $-21.34M |
High Forecast | $8.79M | $8.42M | $7.94M | $-43.33M | $-37.14M | $5.71M | $5.78M | $6.26M | $-19.54M | $6.62M | $7.55M | $6.64M | $7.13M | $-46.77M | $-44.92M | $-20.81M | $-46.99M | $-37.59M | $-45.88M | $-17.07M |
Low Forecast | $-159.07M | $-152.44M | $-143.78M | $-53.33M | $-54.14M | $-103.38M | $-104.65M | $-113.32M | $-41.08M | $-119.88M | $-136.64M | $-120.18M | $-129.09M | $-46.77M | $-44.92M | $-31.22M | $-46.99M | $-37.59M | $-45.88M | $-25.61M |
Surprise % | - | - | - | - | - | - | - | - | 0.99% | 0.24% | 0.60% | 0.62% | 0.58% | 0.52% | 0.61% | 1.01% | 0.53% | 0.59% | 0.17% | 0.77% |
Forecast
4D Molecular Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 5 | 8 |
SG&A | - | - | - | - | - | - | - | - | $10.60M | $9.11M | $8.79M | $7.99M | $8.47M | $8.05M | $8.17M | $8.23M | $7.33M | $8.19M | $6.95M | $5.54M |
Avg Forecast | $854.32K | $569.55K | $575.24K | $601.44K | $5.04M | $5.53M | $4.33M | $4.95M | $27.57M | $2.90M | $4.39M | $2.98M | $1.29M | $2.88M | $2.55M | $3.03M | $3.03M | $1.98M | $1.89M | $8.75M |
High Forecast | $2.01M | $1.34M | $1.35M | $1.41M | $8.82M | $5.58M | $4.33M | $4.95M | $72.61M | $6.81M | $10.31M | $7.01M | $3.02M | $2.88M | $2.55M | $3.03M | $3.03M | $1.98M | $1.89M | $10.50M |
Low Forecast | $97.19K | $64.79K | $65.44K | $68.42K | $62.97K | $5.47M | $4.33M | $4.95M | $1.18M | $329.79K | $499.55K | $339.54K | $146.27K | $2.88M | $2.55M | $3.03M | $3.03M | $1.98M | $1.89M | $7.00M |
Surprise % | - | - | - | - | - | - | - | - | 0.38% | 3.14% | 2.00% | 2.68% | 6.59% | 2.80% | 3.20% | 2.72% | 2.42% | 4.15% | 3.68% | 0.63% |
Forecast
4D Molecular Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 5 | 4 | 5 | 8 |
EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.24 | $-0.77 | $-0.83 | $-0.84 | $-0.74 | $-0.85 | $-0.81 | $-0.93 | $-0.82 | $-0.28 | $-0.61 |
Avg Forecast | $-1.04 | $-1.00 | $-0.94 | $-0.87 | $-0.85 | $-0.68 | $-0.68 | $-0.74 | $-0.61 | $-0.78 | $-0.89 | $-0.79 | $-0.84 | $-0.85 | $-0.81 | $-0.85 | $-0.85 | $-0.68 | $-0.83 | $-1.43 |
High Forecast | $0.16 | $0.15 | $0.14 | $-0.78 | $-0.67 | $0.10 | $0.10 | $0.11 | $-0.35 | $0.12 | $0.14 | $0.12 | $0.13 | $-0.85 | $-0.81 | $-0.85 | $-0.85 | $-0.68 | $-0.83 | $-1.14 |
Low Forecast | $-2.86 | $-2.74 | $-2.59 | $-0.96 | $-0.97 | $-1.86 | $-1.88 | $-2.04 | $-0.74 | $-2.16 | $-2.46 | $-2.16 | $-2.32 | $-0.85 | $-0.81 | $-0.85 | $-0.85 | $-0.68 | $-0.83 | $-1.72 |
Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.31% | 0.86% | 1.06% | 1.00% | 0.87% | 1.05% | 0.95% | 1.09% | 1.21% | 0.34% | 0.43% |
Forecast
4D Molecular Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
IPSC | Century Therapeutics | $1.24 | $15.00 | 1109.68% | Buy |
PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
GOSS | Gossamer Bio | $0.66 | $3.75 | 468.18% | Buy |
FDMT | 4D Molecular Therapeutics | $7.99 | $41.00 | 413.14% | Buy |
BMEA | Biomea Fusion | $6.38 | $22.75 | 256.58% | Buy |
CCCC | C4 Therapeutics | $4.01 | $13.50 | 236.66% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
MLYS | Mineralys Therapeutics | $11.87 | $30.00 | 152.74% | Buy |
REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $56.78 | $60.63 | 6.78% | Buy |